(Q46016939)

English

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis.

scientific article published in November 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

1 reference

based on heuristic

inferred from title

Irene van der Horst-Bruinsma

3

object named as

Irene E van der Horst-Bruinsma

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

author name string

Mirjam K de Vries

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

Izhar C van Eijk

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

Mike J L Peters

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

Michael T Nurmohamed

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

Ben A C Dijkmans

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

Bouke P C Hazenberg

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

Gerrit J Wolbink

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

publication date

1 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

number of pages

7

1 reference

based on heuristic

inferred from page(s)

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

61

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

11

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

1484-1490

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

High intraindividual week-to-week variability in BASDAI and BASFI values: are several evaluations needed before starting or stopping TNFalpha antagonist therapy for spondyloarthropathies?

1 reference

https://api.crossref.org/works/10.1002%2FART.24838

21 January 2018

Serum amyloid a as a useful indicator of disease activity in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.24838

21 January 2018

Acute-phase response, clinical measures and disease activity in ankylosing spondylitis.

1 reference

https://api.crossref.org/works/10.1002%2FART.24838

21 January 2018

Relationship between some acute phase reactants and the Bath Ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.24838

21 January 2018

Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.24838

21 January 2018

ASAS/EULAR recommendations for the management of ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.24838

21 January 2018

International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.24838

21 January 2018

First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis

1 reference

https://api.crossref.org/works/10.1002%2FART.24838

21 January 2018

Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation

1 reference

https://api.crossref.org/works/10.1002%2FART.24838

21 January 2018

Serum amyloid A (SAA): Biochemistry, genetics and the pathogenesis of AA amyloidosis

1 reference

https://api.crossref.org/works/10.1002%2FART.24838

21 January 2018

Identifiers

10.1002/ART.24838

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/19877087

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46016939&oldid=1765810067"